The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemiaDE ROOIJ, Martin F. M; KUIL, Annemieke; GEEST, Christian R et al.Blood. 2012, Vol 119, Num 11, pp 2590-2594, issn 0006-4971, 5 p.Article

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor IbrutinibWOYACH, Jennifer A; FURMAN, Richard R; DAVE, Sandeep S et al.The New England journal of medicine. 2014, Vol 370, Num 24, pp 2286-2294, issn 0028-4793, 9 p.Article

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765HERMAN, Sarah E. M; GORDON, Amber L; HAMDY, Ahmed et al.Blood. 2011, Vol 117, Num 23, pp 6287-6296, issn 0006-4971, 10 p.Article

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell MalignanciesADVANI, Ranjana H; BUGGY, Joseph J; SUKBUNTHERNG, Juthamas et al.Journal of clinical oncology. 2013, Vol 31, Num 1, pp 88-94, issn 0732-183X, 7 p.Article

The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone lossSHINOHARA, Masahiro; CHANG, Betty Y; BUGGY, Joseph J et al.Bone (New York, NY). 2014, Vol 60, pp 8-15, issn 8756-3282, 8 p.Article

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaBYRD, John C; FURMAN, Richard R; JONES, Jeffrey A et al.The New England journal of medicine. 2013, Vol 369, Num 1, pp 32-42, issn 0028-4793, 11 p.Article

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell LymphomaWANG, Michael L; RULE, Simon; BARRIENTOS, Jacqueline C et al.The New England journal of medicine. 2013, Vol 369, Num 6, pp 507-516, issn 0028-4793, 10 p.Article

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myelomaTAI, Yu-Tzu; CHANG, Betty Y; CEA, Michele et al.Blood. 2012, Vol 120, Num 9, pp 1877-1887, issn 0006-4971, 11 p.Article

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivoPONADER, Sabine; CHEN, Shih-Shih; BUGGY, Joseph J et al.Blood. 2012, Vol 119, Num 5, pp 1182-1189, issn 0006-4971, 8 p.Article